Literature DB >> 32169230

Corrections to "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa.   

Abstract

Entities:  

Year:  2020        PMID： 32169230     DOI： 10.1093/annonc/mdy157

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis.

Authors:  Chao Hou; Zhuang-Zhuang Jiang; Bo Pan; Xiao-Chun Zhang; Yan-Qing Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-03       Impact factor: 2.629

Review 2.  Practice guidelines for BRCA1/2 tumour testing in ovarian cancer.

Authors:  Daria Grafodatskaya; Darren D O'Rielly; Karine Bedard; Darci T Butcher; Christopher J Howlett; Alice Lytwyn; Elizabeth McCready; Jillian Parboosingh; Elizabeth L Spriggs; Andrea K Vaags; Tracy L Stockley
Journal:  J Med Genet       Date:  2022-04-07       Impact factor: 5.941

3.  Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.

Authors:  Yamin Shu; Yanxin Liu; Xucheng He; Yufeng Ding; Qilin Zhang
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.